Skip to main content
Clinical Trials/NCT05452850
NCT05452850
Active, Not Recruiting
N/A

Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis: Prognostic Significance

Istanbul University - Cerrahpasa (IUC)1 site in 1 country30 target enrollmentAugust 11, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Amyloid Cardiomyopathy
Sponsor
Istanbul University - Cerrahpasa (IUC)
Enrollment
30
Locations
1
Primary Endpoint
The longitudinal changes in left and right ventricular global strain after chemotherapy in cardiac light chain amyloidosis
Status
Active, Not Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study to assess the longitudinal changes in left and right ventricular global strain after chemotherapeutic strategies in cardiac light chain amyloidosis.

Detailed Description

Light chain amyloidosis is a disease characterized by localized or systemic accumulation of amyloid fibrils in tissues caused by abnormal folding of light chain immunoglobulins and affecting organ functions. In the treatment, chemotherapeutic agents are used that prevent the clonal proliferation of plasma cells in the bone marrow. Although the hematological response is standardized in evaluating the treatment response, there is no adequately effective method for assessing cardiac response. Despite the use of various scores, imaging-based systems continue to be developed to increase the sensitivity of these methods. After being informed about the study, it is planned to recruit and follow-up AL-Amyloidosis patients with cardiac involvement who are currently receiving/planned chemotherapy followed by hematology or who are planned for bone marrow transplantation within 1 year after obtaining written consent from the patients.

Registry
clinicaltrials.gov
Start Date
August 11, 2022
End Date
October 30, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Istanbul University - Cerrahpasa (IUC)
Responsible Party
Principal Investigator
Principal Investigator

Deniz Mutlu

Principal Investigator

Istanbul University - Cerrahpasa (IUC)

Eligibility Criteria

Inclusion Criteria

  • ≥18 years old
  • Patients who give the informed consent
  • Patients with cardiac primary light chain amyloidosis or due to multiple myeloma who are newly diagnosed, currently receiving chemotherapeutic treatment, or are scheduled for bone marrow transplantation

Exclusion Criteria

  • A history of myocardial infarction, coronary artery disease, PCI and revascularization
  • \< 18 years old
  • A history of severe aortic and mitral valve disease
  • Patients who do not give the informed consent
  • A history of severe hypertension (SBP\>180 mmHg or DBP ≥110 mmHg or the need to use three or more antihypertensive agents)
  • Stable coronary artery patients with ischemia data in stress tests (exertion test, myocardial perfusion scintigraphy)
  • Presence of non-amyloidosis, systemic, inflammatory or autoimmune disease
  • Patients whose cardiac imaging is not interpretable

Outcomes

Primary Outcomes

The longitudinal changes in left and right ventricular global strain after chemotherapy in cardiac light chain amyloidosis

Time Frame: Change from Baseline left and right ventricular global strain at 1 year

In this study, the effects of treatment strategies on left and right ventricular global and regional strain and its relationship with mortality and morbidity will be investigated in patients with AL-amyloidosis, who are still under treatment, and newly diagnosed with AL-amyloidosis.

Secondary Outcomes

  • Evaluation of the effects of treatment strategies on other cardiac morphological and functional changes in standard echocardiographic imaging(Baseline, and 1st, 3rd, 6th, 12th Month follow-up)

Study Sites (1)

Loading locations...

Similar Trials